Form 4: Kura Oncology Executive Sells Shares
Insider Transaction (Form 4)
Brian T. Powl, Chief Commercial Officer of Kura Oncology, Inc., sold 32,450 shares of common stock on September 28, 2026.
Summary
- Open-market sale: disposed of 9,020 Common Stock at $10.50 ($94,686) on September 28, 2026; holds 160,249 after (Direct).
- Open-market sale: disposed of 8,000 Common Stock at $10.56 ($84,498) on September 28, 2026; holds 152,249 after (Direct).
- Open-market sale: disposed of 15,430 Common Stock at $10.75 ($165,852) on September 29, 2026; holds 136,819 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $345,036 of stock on the open market.
Insider Transactions
Brian T. Powl — Officer (Chief Commercial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-28 | Open-market sale | Common Stock | 9,020 | $10 | $94.7K | 160,249 |
| 2026-09-28 | Open-market sale | Common Stock | 8,000 | $11 | $84.5K | 152,249 |
| 2026-09-29 | Open-market sale | Common Stock | 15,430 | $11 | $165.9K | 136,819 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-28 | Open-market sale (9,020 shares) |
| 2026-09-28 | Open-market sale (8,000 shares) |
| 2026-09-29 | Open-market sale (15,430 shares) |
Keywords
insider transaction, Form 4, KURA, Kura Oncology, Inc., bearish, Brian T. Powl
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.